Absci announced a new partnership with EQRx, a Cambridge, Massachusetts pharmaceutical company focused on developing lower-cost medicines. The two companies plan to jointly engineer and develop clinical candidates in oncology and immunology, in addition to other therapeutic areas.
After raising more than $230M in July through its IPO, the Vancouver, Washington-based company is continuing on a positive trajectory with plans to grow in the future.
“This collaboration with EQRx expands the reach of our AI-powered target discovery, drug design and development technology,” said Sean McClain, founder and CEO of Absci.